Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Fabrizio Ganzina"'
Autor:
Nicola Di Pietro, Roberto Latagliata, Luigi Resegotti, Maria Concetta Petti, Francesco Nobile, Franco Mandelli, Saverio Ladogana, Nicola Petti, Claudio Malleo, Emanuela Falconi, Bruno Rotoli, Giorgina Specchia, Fabrizio Ganzina, Enrico Geraci, Alfredo Ardia, Francesco Di Raimondo, Antonio Tabilio
Publikováno v:
European Journal of Cancer and Clinical Oncology. 27:750-755
255 patients with acute non-lymphoid leukaemia (ANLL), observed between October 1984 and June 1987, entered a chemotherapy regimen consisting of induction therapy with cytarabine in combination with idarubicin (IDA/ARA) or daunorubicin (DNR/ARA), fol
Autor:
Cerri R, Fabrizio Ganzina, Angela Congiu, Gino Santini, Martinengo M, Eugenia Gaozza, Alberto M. Marmont, Angelo Michele Carella, Sandro Nati, Domenico Giordano, Eugenio Damasio, Marco Risso
Publikováno v:
European Journal of Cancer and Clinical Oncology. 23:1673-1678
Thirty-one unselected patients with untreated acute non lymphoblastic leukemia (ANLL) ranging in age from 15 to 76 years received two courses of a new high-dose induction regimen consisting of idarubicin, etoposide and cytarabine. Patients who entere
Autor:
Fabrizio Ganzina
Publikováno v:
Tumori Journal. 65:563-585
Medroxyprogesterone acetate (MPA) when employed at high doses (greater than or equal to 500 greater than or equal to 1000 mg/day i.m.) can produce objective remission with improved survival in about 30% of postmenopausal women with advanced breast ca
Autor:
Fabrizio Ganzina
Publikováno v:
Cancer Treatment Reviews. 10:1-22
4'-epi-doxorubicin (4'-epi-DX) is a new anthracycline antibiotic. It differs from doxorubicin (DX) by the epimerization of the OH group in position 4' of the aminosugar moiety, and was synthesized in an effort to find agents with a superior therapeut
Autor:
Claudio Annaloro, Fabrizio Ganzina, Giorgio Lambertenghi-Deliliers, Anna Teresa Maiolo, Agostino Cortelezzi, Elio Polli, Enrico Pogliani
Publikováno v:
European Journal of Cancer and Clinical Oncology. 23:1041-1045
Sixteen adult patients with refractory acute non-lymphoblastic leukemia (ANLL) underwent reinduction therapy with idarubicin (12 mg/m 2 ) i.v. on days 1–3) followed by cytosine arabinoside (120 mg/m 2 every 120 h on days 4–10). Patients achieving
Autor:
E. Ferrazzi, Giuseppe Maraglino, Piero Pagnin, Fabrizio Ganzina, Mario V. Fiorentino, Ornella Nicoletto, Orazio Vinante
Publikováno v:
Tumori Journal. 68:431-435
Sixty-five patients with advanced solid tumors were treated with 4'epi-doxorubicin, a new analogue of doxorubicin (DXR). Forty-three of 61 evaluable patients had not received previous chemotherapy and/or hormonal treatment. 4'Epi-doxorubicin has been
Publikováno v:
Investigational new drugs. 4(1)
4-Demethoxydaunorubicin (4-DMDR, IMI 30, Idarubicin, NSC 256439) is a new analog of daunorubicin (DNR) with antileukemic activity in experimental systems that is superior to that of daunorubicin (DNR) or doxorubicin (DX). The drug is more potent than
Autor:
Fabrizio Ganzina, Luciana Tomasi, Gildino Farabegoli, Franco Pannuti, Andrea Martoni, Nino Monetti, Michele Giovannini
Publikováno v:
European journal of cancerclinical oncology. 20(1)
4′ -Epi-doxorubicin ( 4′ -epi-DX) is a new doxorubicin derivative that in phase II human studies has been demonstrated to be less toxic than doxorubicin. Sixty-four patients with advanced solid tumors were treated with the drug combination of 4